Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence study of SYS6012 versus Cosentyx in moderate to severe plaque psoriasis
CTR20241390Phase 3Completed
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SYS6012, secukinumab in plaque psoriasis, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jun 2024; status: completed.
02
Drugs
SYS6012secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20241390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241390.